While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

(RTTNews) - InflaRx N.V. (IFRX) today released detailed analyses from its terminated Phase 3 trial of Vilobelimab in pyoderma gangrenosum. The study was stopped in May 2025 after an Independent Data ...

InflaRx (IFRX) outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

Leg ulcers form when skin on your leg breaks open. These breaks or sores let air and bacteria travel into your skin’s tissue. For most people, leg ulcers will heal on their own and won’t need medical ...

Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...

People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...